Back to enarahealth.com Enara for patients
Research

Evidence from the Enara model

Conference posters and clinical research from our team and partners on hybrid obesity care, outcomes, and cardiometabolic health.

Study flow chart for the 36-month non-AOM cohort
OMA 2026

Care Factors Associated With Sustained 15% Weight Loss at Three Years in Patients Not Taking AOMs

1 in 5 Enara patients lost over 15% of their weight at 3 years - with no medications. Consistent, digital-first engagement set the high achievers apart.

April 1, 2026
Skeletal muscle mass preservation framework
OMA 2026

Beyond Weight Loss Percent: Key Factors Associated With SMM Preservation in an Obesity Care Program

Not all weight loss is good weight loss. High achievers preserved skeletal muscle mass while losing fat - and the difference came from dietary and pharmacological intensity, not exercise volume.

April 1, 2026
hsCRP change at 3, 6, and 12 months for AOM and non-AOM participants
OMA 2026

Hybrid Obesity Care Reduces Inflammation at 12 Months in Adults With Obesity

Both AOM and non-AOM participants showed reduced systemic inflammation at 12 months, with hsCRP reductions of -1.22 mg/L and -2.10 mg/L respectively. No significant between-group differences were found, suggesting the hybrid program itself is associated with inflammatory improvement.

April 1, 2026
Weight loss outcomes comparing Medicaid and commercial insurance with and without AOMs
OMA 2026

Impact of Medicaid vs Commercial Insurance Status on Weight Loss Outcomes With and Without AOMs

Even when motivation is the same, access isn't. This study shows that Medicaid patients can achieve outcomes comparable to commercially insured peers when given access to anti-obesity medications.

April 1, 2026
ACC 2026

A Digital Cardiology-Embedded Obesity Platform Produces Sustained Clinical and Financial Outcomes, Redefining Cardiovascular Prevention

Over 70% of patients maintained at least 10% weight loss at 18 months, with more than 40% achieving 15% loss, alongside meaningful improvements in blood pressure, cholesterol, and HbA1c. The model also generates $311 per patient per month, creating a new revenue stream for practices.

March 1, 2026